2892 - Safety and Immunogenicity of mRNA-1647, an mRNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results of a Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial

Co-Author(s)

• 

  Lori Panther, MD, MPH

  Senior Director
  Moderna, Inc.
  Cambridge, Massachusetts, United States

Presenting Author(s)

• SB

  Sandeep Basnet, MD

  Moderna, Inc.
  Cambridge, MA, United States

  Slides

Co-Author(s)

• CF

  Carlos Fierro, M.D.

  Investigator
  Johnson County Clin-Trials
  Lenexa, Kansas, United States
• DB

  Daniel Brune, MD

  Optimal Research
  Peoria, Illinois, United States
• RL

  Richard Leggett, DO

  Crossroads Clinical Research
  Victoria, Texas, United States
• JP

  James Peterson, MD

  Foothill Family Clinic
  Salt Lake City, Utah, United States
• PP

  Paul Pickrell, MD

  Tekton Research
  Austin, Texas, United States
• JL

  Jiang Lin, PhD

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• KW

  Kai Wu, PhD

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• HL

  Heather Lee, BS

  Director
  Moderna, Inc.
  Cambridge, Massachusetts, United States
• RH

  Roxane Hasselbeck, BA

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• AN

  Andrew Natenshon, MA

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• JM

  Jacqueline Miller, MD

  Moderna, Inc.
  Cambridge, Massachusetts, United States